Regulatory and Compliance Updates news

• 

  21 May 2026

  Rely wins Power2X EPC for 20MW Djewels green hydrogen plant in Delfzijl

  Project reached FID/NTP and moves into construction. Will use John Cockerill pressurized alkaline electrolysis; first hydrogen expected mid‑2028; plant ties into local Chemical Park and Nobian.
• 

  21 May 2026

  PureCycle and Reliable Caps launch closures made with PureFive recycled polypropylene (up to 75% PCR)

  Bright white, colorable closures using certified, domestically sourced recycled PP; FDA-grade and GreenCircle‑certified, suited for contact‑sensitive food, beverage and personal‑care packaging.
• 

  21 May 2026

  Hycamite plans 200 kt/yr graphite plant in Finland

  EU CRMA status and new tech enable a phased Finnish project: Phase 1 demo starts next year; full scale could reach 200 kt/yr (~40% of EU battery graphite demand), serving batteries and industry.
• 

  20 May 2026

  BASF and Cromology convert end‑of‑life tires into binder for Tollens Maxiline+ wall paint

  Chemically recycled styrene-acrylate binder from tire pyrolysis oil used in interior wall paint via mass-balance. REDcert² certified; 10 L ≈ 2 tires; reduces fossil feedstock and CO₂.
• 

  19 May 2026

  European Commission unveils Fertiliser Action Plan to secure EU fertiliser supply and food security

  Immediate liquidity relief and CAP flexibility for farmers; boost domestic, low‑carbon and circular production; improve market transparency, monitoring, and preparedness.
• 

  19 May 2026

  Statkraft to invest NOK 80bn in Norwegian hydropower over 10 years

  Half for major maintenance; rest for upgrades, new capacity and wind repowering. Nationwide dam reinforcements, turbine and tunnel refurbishments; projects need permits and profitability

• 

  18 May 2026

  Boehringer Ingelheim's JASCAYD (nerandomilast) approved in Japan for IPF and PPF

  First oral PDE4B inhibitor shows slowed FVC decline in FIBRONEER Phase III; pooled analysis showed 59% nominal death reduction. Common AE: diarrhea; EU/UK reviews ongoing.
• 

  18 May 2026

  Genentech to present ASCO 2026 data on giredestrant in early ER+ breast cancer

  Presents data on nine drugs across 15+ indications: breast‑cancer first‑line/post‑progression analyses, HER2 brain‑penetrant TKI, KRAS G12C+pembrolizumab, and lymphoma ADC/bispecific combo
• 

  18 May 2026

  NRC Issues FONSI for Dow and X-energy Long Mott Nuclear Project in Texas

  NRC completed an Environmental Assessment and issued a FONSI for a proposed advanced SMR at Seadrift, Texas, clearing a key Construction Permit step to supply electricity and industrial steam.
• 

  18 May 2026

  Essar Energy Transition completes Pre‑FEED for Stanlow Methanol‑to‑Jet SAF hub

  Planned plant will convert ~550,000 tpa renewable methanol into >200,000 tpa jet fuel, using existing refinery blending and pipeline export; FEED this year, FID by early 2028.
• 

  18 May 2026

  Chugai’s Alecensa Gets World-First Tumor‑Agnostic Approval for ALK‑Positive Solid Tumors

  Japan approves tumor‑agnostic ALK inhibitor for ALK‑fusion solid tumors including pediatrics. TACKLE Phase II showed 70–76% response in ALK‑fusion cases; safety consistent. FoundationOne CDx approved.
• 

  18 May 2026

  Chugai: MHLW approves FoundationOne CDx as Alecensa companion diagnostic for ALK‑positive solid tumors

  TACKLE Phase II supported Alecensa's efficacy/safety, enabling a partial marketing-authorization change; FoundationOne CDx expands tumor-agnostic genomic profiling and treatment options.
• 

  18 May 2026

  GSK’s Arexvy gains expanded approval in Japan for at‑risk adults 18–59

  Approval now explicitly includes immunocompromised adults; Phase IIIb showed non‑inferior immune response versus older adults and a safety profile consistent with prior trials.
• 

  15 May 2026

  Genentech’s Tecentriq approved by FDA as ctDNA‑guided adjuvant therapy for MIBC

  FDA approves first ctDNA‑MRD‑guided adjuvant option for muscle‑invasive bladder cancer. IMvigor011: ctDNA+ patients had 36% reduced DFS risk and 41% reduced OS risk; Signatera CDx authorized.
• 

  15 May 2026

  EnviTec Biogas: solid 2025; regulatory setbacks dent 2026, growth expected from 2027

  Total output +6.8% to €376.4M; revenues -7.4% to €312.6M; EBT €26.0M (prev €44.0M) after ~€8M provision; dividend suspended. 2026 guidance: revenues €330–370M, EBT €5–15M.
• 

  14 May 2026

  PureCycle: NJDEP Qualifies PureFive® Resin as Recycled Content

  NJDEP grants one-year conditional PCR designation under NJ recycled-content law; firm will seek permanent approval. Resin cleared for food-contact rigid packaging; 10.5M lb NJ feedstock sourced 2025
• 

  14 May 2026

  Iberdrola begins commissioning Tâmega wind‑hydro complex

  Tâmega Norte enters commissioning as the Iberian Peninsula's first grid-connected wind‑hydro hybrid: 195 MW (27×7.2 MW), ~414 GWh/yr; €346M for both farms; >230,000 t CO2/yr avoided.
• 

  14 May 2026

  Chugai, Nippon Shinyaku file Gazyva (obinutuzumab) for idiopathic nephrotic syndrome

  Phase III INShore showed improved sustained remission and steroid reduction versus MMF; no new safety signals, supporting a regulatory application.
• 

  14 May 2026

  Johnson Matthey 2026 PGM Market Report

  PGM prices surged; platinum hit record. 2026: deficits likely for platinum, ruthenium, iridium; palladium and rhodium may have small surpluses. Strong prices boost recycling; industrial demand firm.
• 

  14 May 2026

  Sinopec confirms 2,356.87 bcm proven reserves at Ziyang Dongfeng ultra-deep shale gas field

  Cambrian Qiongzhusi shale at 4,500–5,200 m poses high-temp, high-pressure, hard-to-drill reservoir challenges. Team developed new geological model, AI imaging and ultra‑deep drilling/fracturing tech.
• 

  12 May 2026

  Messer Belgium builds sustainable air separation plant at North Sea Port

  €60M investment creates 30 jobs to produce oxygen, nitrogen and argon; construction starts mid‑May, commissioning by 2028, CO2‑free operation using green electricity; serves Lille‑Rotterdam axis
• 

  12 May 2026

  ABO Energy achieves restructuring milestones and defines strategic priorities

  Restructuring draft finds firm viable; sets strategic action areas. Targets sustainable financing by end-July. Won 7.8 MW solar tariff, bid >150 MW wind, sold 16.8 MW farm and 4.5 MW turbine.
• 

  12 May 2026

  Eni and MSC Cruises test Enilive HVO diesel on cruise ship

  Pure HVO ran ~2,000 hours on a ship engine with no modifications; matched fuel performance, cut NOx ~16% and particulates, and cut lifecycle GHG ~80%. Validated by maker and independent certifier.
• 

  11 May 2026

  LanzaTech selects North Sea Port, Ghent for Europe’s first commercial ATJ SAF plant

  €500M ATJ project targeting 79,000 t/yr SAF and 9,000 t/yr renewable diesel; EIA scoping filed; ~50 permanent jobs and ~300 FTE construction; FEED complete; EU Horizon support.
• 

  11 May 2026

  Ørsted and PGE start Baltica 2 offshore installation

  First foundations installed for a 1.5 GW offshore wind farm. 111 monopiles (107 turbine, 4 substation) to be installed through Q4 2026; commissioning expected in 2027; 25-yr CfD.
• 

  11 May 2026

  GSK partners with Sino Biopharmaceutical (CTTQ) for exclusive China launch of bepirovirsen

  Potential first-in-class CHB treatment under priority review in China; deal provides access to 5,000+ medical centres at launch, local import/distribution, hospital access and initial 5.5-yr supply.
• 

  9 May 2026

  Uniper demolishes Scholven towers D & E for H2-ready CCGT

  Two 114 m cooling towers were demolished at 11:00; ~15,000 t of concrete will be recycled for site backfill. Demolition used a coordinated safety plan; no resident evacuations.
• 

  8 May 2026

  argenx: FDA expands VYVGART/VYVGART Hytrulo approval to all adult gMG patients

  Phase-3 ADAPT SERON: VYVGART showed rapid, significant, sustained improvements across anti-MuSK, anti-LRP4 and triple-seronegative gMG; safety consistent; IV/SC options; access support.
• 

  8 May 2026

  Clariant Q1 2026: Resilient performance amid Middle East conflict

  Q1 sales down 2% (CHF918m); EBITDA margin fell to 17.5% (-130bp). Free cash-flow conversion rose to 54%. CHF80m savings program on track; 2026 guidance unchanged amid conflict
• 

  8 May 2026

  MOL Group Q1 2026: USD 212m profit amid supply disruptions and price controls

  Higher hydrocarbon prices lifted upstream; production 95.5 mboepd. Downstream hit by lower refining volumes and feedstock scarcity; Rijeka delayed coker opened. Consumer services and circulars rose.